WongND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276–289.
2.
MontalescotGSechtemUAchenbachS. 2013ESC Guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013;34(38):2949–3003.
3.
Marquis-GravelGTardifJ-C. Ivabradine: the evidence of its therapeutic impact in angina. Core Evid. 2008;3(1):1–12.
4.
GiannoglouGDChatzizisisYSZamboulisCParcharidisGEMikhailidisDPLouridasGE. Elevated heart rate and atherosclerosis: an overview of the pathogenetic mechanisms. Int J Cardiol. 2008;126(3):302–312.
5.
ChatzizisisYSCoskunAUJonasMEdelmanERFeldmanCLStonePH. Role of endothelial shear stress in the natural history of coronary atherosclerosis and vascular remodeling: molecular, cellular, and vascular behavior. J Am Coll Cardiol. 2007;49(25):2379–2393.
6.
KwakBRBackMBochaton-PiallatML. Biomechanical factors in atherosclerosis: mechanisms and clinical implications. Eur Heart J. 2014;35(43):3013–3020, 3020a-3020d.
7.
GiannoglouGDChatzizisisYS. Heart rate lowering reduces cardiovascular disease burden. Curr Med Res Opin. 2014;30(9):1757.
8.
ChatzizisisYSGiannoglouGD. Importance of local hemodynamic conditions in the atherosclerotic effect of increased heart rate. J Am Coll Cardiol. 2011;57(21):2206;author reply 2206.
9.
JoannidesRMooreNIacobM. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol. 2006;61(2):127–137.
10.
TardifJCFordITenderaMBourassaMGFoxK; INITIATIVE Investigators. Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26(23):2529–2536.
11.
TardifJCPonikowskiPKahanT; ASSOCIATE Investigators. Effects of ivabradine in patients with stable angina receiving beta-blockers according to baseline heart rate: an analysis of the associate study. Int J Cardiol. 2013;168(2):789–794.
12.
TardifJCPonikowskiPKahanT; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009;30(5):540–548.
13.
TenderaMBorerJSTardifJC. Efficacy of I(f) inhibition with ivabradine in different subpopulations with stable angina pectoris. Cardiology. 2009;114(2):116–125.
14.
ZarifisJGrammatikouVKalilistratosMKatsivasA. Antianginal efficacy of ivabradine in patients with history of coronary revascularization. Angiology. 2017;68(1):10–18.
15.
WijeysunderaHCTomlinsonGNorrisCMGhaliWAKoDTKrahnMD. Predicting EQ-5D utility scores from the Seattle Angina Questionnaire in coronary artery disease: a mapping algorithm using a Bayesian framework. Med Decis Making. 2011;31(3):481–493.
16.
WerdanKEbeltHNudingSHopfnerFHackGMuller-WerdanU. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the additions study. Clin Res Cardiol. 2012;101(5):365–373.
17.
BorerJSFoxKJaillonPLereboursG; Ivabradine Investigators Group. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003;107(6):817–823.
18.
GoldbergerJJBonowROCuffeM; OBTAIN Investigators. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66(13):1431–1441.
19.
TaquetiVRO’GaraPT. Beta-blocker therapy after myocardial infarction: more questions than answers. J Am Coll Cardiol. 201566(13):1442–1444.
20.
WerdanKEbeltHNudingSHopfnerFStocklGMuller-WerdanU. Ivabradine in combination with beta-blockers in patients with chronic stable angina after percutaneous coronary intervention. Adv Ther. 2015;32(2):120–137.
21.
FoxKFordIFerrariR. Ivabradine in stable coronary artery disease. N Engl J Med. 2014;371(25):2435.
22.
BeltrameJF. Ivabradine and the SIGNIFY conundrum. Eur Heart J. 2015;36(46):3297–3299.
23.
FerrariRFoxKM. The role of heart rate may differ according to pathophysiological setting: From SHIFT to SIGNIFY. Eur Heart J. 2015;36(31):2042–2046.
24.
FoxKFordIStegPGTardifJCTenderaMFerrariR; SIGNIFY Investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371(12):1091–1099.
